# Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -

> **NCT04647604** · PHASE2 · COMPLETED · sponsor: **Karolinska University Hospital** · enrollment: 23 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Omegaven®
- **DRUG:** Sodium chloride

## Key facts

- **NCT ID:** NCT04647604
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-23
- **Primary completion:** 2021-01-05
- **Final completion:** 2021-07-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04647604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04647604, "Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04647604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*